In medicine, a physician is often faced with two kinds of conundrums: first, in the absence of overt visual changes in symptoms, how to tell if the treatment is working? Second, in the presence of a certain set of symptoms, is the treatment regimen sufficient or requires modification? The Investigative Proteomics Laboratory at NNF aims to solve these two conundrums by realizing the root molecular cause of any abnormality or disease and utilizing the knowledge accrued to give real-time data to a physician. In order to achieve this goal, we will utilize our high end mass spectrometry instrument (nano-LC MS/MS) to obtain fine resolution protein and metabolite profiling of any given input sample. This line of translational research will lead to disease specific molecular signatures that can give the physician a new set of tools to better diagnose and manage disease.
Research concept of tear proteomics
Tears are representative of not only the condition of the lacrimal gland or ocular surface, but also of the overall status of the individual’s body. Several studies on tear proteomics have highlighted the power of biomarker discovery by mass spectrometry in diseases of different kinds, especially in ocular diseases like dry eye or systemic diseases like SJS or even cancer (breast cancer biomarkers). Such studies can be done theoretically, from patient tears for any given disease provided normative data can be obtained from appropriate age, sex and race matched control healthy populations. By analyzing the levels of deregulated proteins in tears of patients, we can determine the pathways that are affected in the patients. These data on deregulated proteins, when correlated tightly with disease stages can thus be used for disease prediction. On another aspect the data will tell us about the underlying pathways that are affected during disease pathogenesis, some of these pathways and proteins will be novel and provide insights or targets for novel or repurposed drug development.
Tear Fluid Proteome
Targeted proteomics- From Lab to Clinic
Establish disease specific proteomic fingerprints of probable molecular markers of disease by targeted quantitative proteomic assays using multiple reaction monitoring (MRM), correlate with clinical or epidemiological parameters and fine tune treatment in patients on the basis of modulation of specific biomarkers